Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention
Launched by LUCILAB · Dec 21, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Luci program, is studying how lifestyle changes can help reduce the risk of dementia for middle-aged and older adults. Researchers believe that by improving habits like staying mentally active, exercising regularly, and eating a healthy diet, people may lower their chances of experiencing cognitive decline, which is a loss of thinking skills. The goal of the trial is to see if the Luci program, which includes online coaching and support, can effectively help participants make these positive changes in their lives.
To participate, you should be between the ages of 50 and 75, be comfortable using a computer or tablet, and speak either French or English. You’ll be eligible if you currently have low levels of mental engagement, do not get enough physical activity, or do not follow a healthy diet. However, if you have been diagnosed with dementia, have certain medical conditions, or have recently had major health issues, you may not be able to join the study. Throughout the trial, participants can expect guidance and support to help them improve their daily habits, contributing to a healthier lifestyle and potentially reducing their dementia risk.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Aged between 50 and 75;
- • Proficient or native speakers in French or English;
- • Computer literate defined as being able to read mails and browse the Internet, and having access to a computer or tablet with an Internet connection;
- * Eligible in at least one of the 3 intervention domains, where eligibility is defined as follows:
- • Low cognitive engagement in cognitively stimulating activities, defined as a score ≤ 22 on the adapted Cognitive Activity Questionnaire;
- • Low level of physical activity defined as less than 150 minutes/week) of moderate to vigorous physical activity measured using the Godin- Shephard Leisure Time Physical Activity Questionnaire, and no medical contraindication to physical activity based on the Physical Readiness Questionnaire for Everyone (PAR-Q+);
- • Low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale, and no dietary restriction, severe allergy or intolerance or history of eating disorder.
- Exclusion Criteria :
- • Presence of a cognitive impairment as measured by the Creyos Dementia Assessment;
- • General anesthesia within the last 6 months;
- • Previous participation in the Luci program or in any validation studies related to the program;
- • Current participation in another study;
- • Unable to commit participation over the period of the study;
- • Being in the precontemplation stage of change;
- • High level of perceived stress;
- * Having received a diagnosis of :
- • Dementia or neurodegenerative disease (AD and other dementias);
- • Past or present neurological disorder (multiple sclerosis, brain tumour, epilepsy, stroke, traumatic brain injury);
- • Severe psychiatric disorder (schizophrenia, major depression, bipolar disorder);
- • Diabetes or hypertension without medical monitoring;
- • Alcoholism or drug addiction;
- • Any other condition expected to limit participation (e.g., low visual acuity).
About Lucilab
Lucilab is a pioneering clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing cutting-edge therapies and solutions, Lucilab collaborates with healthcare professionals, researchers, and regulatory bodies to streamline the clinical trial process. By leveraging state-of-the-art technology and data analytics, Lucilab aims to enhance patient outcomes and accelerate the delivery of novel treatments to the market. Committed to maintaining the highest ethical standards, Lucilab prioritizes patient safety and transparency throughout all phases of its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported